Pulmatrix, Inc. (NASDAQ:PULM) Sees Large Growth in Short Interest

Pulmatrix, Inc. (NASDAQ:PULM) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 11,368 shares, an increase of 164.4% from the December 15th total of 4,299 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average daily volume of 49,488 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 49,488 shares, the short-interest ratio is presently 0.2 days. Approximately 0.3% of the shares of the company are short sold.

Institutional Investors Weigh In On Pulmatrix

A hedge fund recently raised its stake in Pulmatrix stock. SBI Securities Co. Ltd. grew its position in Pulmatrix, Inc. (NASDAQ:PULM) by 15.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 60,565 shares of the biotechnology company’s stock after acquiring an additional 8,208 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Pulmatrix were worth $418,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 11.84% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulmatrix in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Pulmatrix currently has a consensus rating of “Sell”.

Pulmatrix Price Performance

NASDAQ:PULM traded up $0.16 during midday trading on Thursday, hitting $2.53. The company’s stock had a trading volume of 32,064 shares, compared to its average volume of 19,636. Pulmatrix has a fifty-two week low of $2.15 and a fifty-two week high of $10.40. The firm has a market cap of $9.23 million, a P/E ratio of -1.49 and a beta of 1.67. The firm’s 50 day moving average is $3.64 and its 200-day moving average is $4.67.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings data on Thursday, October 16th. The biotechnology company reported ($0.24) EPS for the quarter.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).